Accelerating the development of pediatric cancer therapeutics and diagnostics will be a key focus for the US FDA’s new Oncology Center of Excellence (OCE).
“As part of the newly formed Oncology Center of Excellence, one of our top priorities is to do what we can to help move pediatric oncology drug development forward,” Division of Oncology Products 2 Acting Associate Director Martha Donoghue
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?